New drug combined with bladder treatment for early-stage bladder cancer

Plain-English translation of NCT07646145 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing , a new intravenous medication, combined with mitomycin C, a medicine delivered directly into the bladder. The study wants to see if this combination can reduce the chance of cancer coming back and help patients avoid major bladder surgery.

Some bladder cancer patients don't respond well to standard treatments like BCG therapy, so researchers are looking for new options that might be more effective at preventing the cancer from returning while preserving the bladder.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with early-stage bladder cancer that has not spread to muscle or other parts of your body
you have already had bladder surgery (TURBT) to remove the tumor
your cancer cells show specific markers called HER2 expression
you have not responded well to BCG therapy or prefer not to receive it

You likely don't qualify if…

you have a history of bladder cancer that invaded the muscle layer or spread to other organs
you have other tumors in your urinary system
you received other cancer treatments in the past 3 weeks
you have serious heart problems, active infections, or liver or kidney disease that is not controlled
you have a known allergy to the medication or similar drugs

What participation looks like

You will receive the new medication through an IV infusion and also receive mitomycin C treatment directly into your bladder according to a treatment schedule set by the study. The trial will monitor your health with imaging scans and lab tests to see how well the treatment works and watch for any side effects. The study is enrolling 30 patients total at a cancer hospital in Shanxi Province, China.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(1 site)

China

Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi